Use of small pulmonary vascular alterations to identify different types of pulmonary hypertension: a quantitative computed tomography analysis

Abstract

BACKGROUND:

The morphological alterations of small pulmonary vessels measured by computed tomography (CT) is increasingly used in evaluation of suspected pulmonary hypertension (PH).

OBJECTIVE:

To investigate the significance alterations of quantitative assessment of small pulmonary vessels on chest CT in distinguishing different types of PH and their severity.

METHODS:

We retrospectively analyzed a dataset of 120 healthy controls (HCs) and 91 PH patients, including 34 patients with connective tissue diseases-related PH (CTD-PH), 26 patients with idiopathic pulmonary arterial hypertension (iPAH), and 31 patients with chronic obstructive pulmonary disease-related PH (COPD-PH). The CTD-PH patients were divided into mild to moderate PH (CTD-LM-PH) group (n = 17) and severe PH (CTD-S-PH) group (n = 17). A total of 53 CTD patients without PH (CTD-nPH) were enrolled for comparison with the CTD-PH. We measured the cross-sectional area of small pulmonary vessels < 5 mm² (%CSA_<5) and between 5–10 mm² (%CSA_5–10) as a percentage of total lung area among the populations included above and compared %CSA in different types of PH groups and HCs group. The mean pulmonary arterial pressure (mPAP) was measured by right heart catheterization.

RESULTS:

The %CSA_5–10 of COPD-PH, CTD-PH, and iPAH patients increased (0.21±0.09, 0.49±0.20 and 0.61±0.20, p < 0.02) sequentially, while the %CSA_<5 of CTD-PH, iPAH, and COPD-PH patients decreased (0.79±0.65, 0.65±0.38 and 0.52±0.27, p < 0.05) sequentially. The %CSA_5–10 was significantly higher in CTD-S-PH patients than CTD-LM-PH patients and CTD-nPH patients (0.51±0.21, 0.31±0.15 and 0.28±0.12, p < 0.01). The %CSA_5–10 was positively correlated with mPAP in the CTD-PH group.

CONCLUSIONS:

The quantitative parameters %CSA_<5 and %CSA_5–10 assessed by chest CT are useful for distinguishing different types of PH. In addition, the %CSA_5–10 can provide information for identification of CTD-PH severity.

Keywords

Small pulmonary vessels pulmonary hypertension (PH)computed tomography (CT)PH severity classification

Get full access to this article

View all access options for this article.

References

Galie

, Humbert

, Vachiery

J.L.

, et al., ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT), Eur Heart J 37 (1) (2016), 67–119.

Zhao

, Wang

, Liu

, et al., Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: A cohort study in China, Int J Cardiol 236 (2017), 432–437.

Siddiqui

, Rajagopal

, Brucker

, et al., Clinical and echocardiographic predictors of outcomes in patients with pulmonary hypertension, Am J Cardiol 122(5) (2018), 872–878.

Coste

, Dournes

, Dromer

, et al., CT evaluation of small pulmonary vessels area in patients with COPD with severe pulmonary hypertension, Thorax 71(9) (2016), 830–837.

Freed

B.H.

, Collins

J.D.

, Francois

C.J.

, et al., MR and CT Imaging for the Evaluation of Pulmonary Hypertension, JACC Cardiovasc Imaging 9(6) (2016), 715–732.

Ley

, Grunig

, Kiely

D.G.

, et al., Computed tomography and magnetic resonance imaging of pulmonary hypertension: Pulmonary vessels and right ventricle, , J Magn Reson Imaging 32(6) (2010), 1313–1324.

Mahammedi

, Oshmyansky

, Hassoun

P.M.

, et al., Pulmonary artery measurements in pulmonary hypertension: the role of computed tomography, J Thorac Imaging 28(2) (2013), 96–103.

Coste

, Benlala

, Dournes

, et al., Quantitative CT assessment of bronchial and vascular alterations in severe precapillary pulmonary hypertension, Int J Chron Obstruct Pulmon Dis 14 (2019), 381–389.

Shimizu

, Tsujino

, Sato

, et al., Performance of computed tomography-derived pulmonary vasculature metrics in the diagnosis and haemodynamic assessment of pulmonary arterial hypertension, Eur J Radiol 96 (2017), 31–38.

10.

Siegel

, Bleicher

, Gordon

M.K.

, et al., Computed tomography pulmonary angiogram dynamic parameter correlation with pulmonary pressure and pulmonary hypertension etiologies, J Comput Assist Tomogr 41(5) (2017), 779–783.

11.

Matsuoka

, Washko

G.R.

, Yamashiro

, et al., National emphysema treatment trial research, pulmonary hypertension and computed tomography measurement of small pulmonary vessels in severe emphysema, Am J Respir Crit Care Med 181(3) (2010), 218–225.

12.

Matsuoka

, Washko

G.R.

, Dransfield

M.T.

, et al., Quantitative CT measurement of cross-sectional area of small pulmonary vessel in COPD: correlations with emphysema and airflow limitation, Acad Radiol 17(1) (2010), 93–99.

13.

Uejima

, Matsuoka

, Yamashiro

, et al., Quantitative computed tomographic measurement of a cross-sectional area of a small pulmonary vessel in nonsmokers without airflow limitation, Jpn J Radiol 29(4) (2011), 251–255.

14.

McLaughlin

V.V.

, Shah

S.J.

, Souza

, et al., Management of pulmonary arterial hypertension, J Am Coll Cardiol 65(18) (2015), 1976–1997.

15.

Brown

J.W.

, Heath

and Whitaker

Idiopathic pulmonary hypertension, Br Heart J 19(1) (1957), 83–92.

16.

Shimoda

L.A.

and Laurie

S.S.

Vascular remodeling in pulmonary hypertension, J Mol Med (Berl) 91(3) (2013), 297–309.

17.

Tuder

R.M.

, Archer

S.L.

, Dorfmuller

, et al., Relevant issues in the pathology and pathobiology of pulmonary hypertension, J Am Coll Cardiol 62 (2013), D4–12.

18.

Pietra

G.G.

, Capron

, Stewart

, et al., Pathologic assessment of vasculopathies in pulmonary hypertension, J Am Coll Cardiol 43 (2004), 25S–32S.

19.

Zanatta

, Polito

, Famoso

, et al., Pulmonary arterial hypertension in connective tissue disorders: Pathophysiology and treatment, Exp Biol Med (Maywood) 244(2) (2019), 120–131.

20.

Rabinovitch

, Guignabert

, Humbert

, et al., Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension, Circ Res 115(1) (2014), 165–75.

21.

Thenappan

, Ormiston

M.L.

, Ryan

J.J.

, et al., Pulmonary arterial hypertension: pathogenesis and clinical management, BMJ 360 (2018), j5492.

22.

Thompson

A.A.R.

and Lawrie

Targeting vascular remodeling to treat pulmonary arterial hypertension, Trends Mol Med 23(1) (2017), 31–45.

23.

Rabinovitch

Molecular pathogenesis of pulmonary arterial hypertension, J Clin Invest 122(12) (2012), 4306–4313.